Company

Founded in September 2019, we are a team of experienced AI/machine learning and business specialists applying state of the art generative AI to drug discovery in close collaboration with biopharmaceutical partners to bring new therapeutics to market across disease areas and positively impact lives.

Our Team

We are a team of experienced AI/machine learning and business specialists applying state of the art generative AI to drug discovery in close collaboration with biopharmaceutical partners to bring new therapeutics to market across disease areas and positively impact lives.

Handol Kim

Mehran Khodabandeh

Zac Alperstein

Peter Guzzo

Roslynn Drewitt-Lange

Marshall Drew-Brook

Marawan Ahmed

Jason Rolfe

Artem Cherkasov

Ali Saberali

Ahmad Issa

Board, Observers & Outsiders

John BoylanPhD, SAB Member (Cell Biology/Oncology drug discovery)

Nancy HarrisonAdvisor (Strategy/ Commercial)

Mads DaugaardPhD, SAB Member (Oncology Biology)

Jennifer HamiltonPhD, Advisor (Strategy/Commercial)

Robert N. YoungPhD, SAB Member (Medicinal Chemistry)

Alexander TropshaPhD, SAB Member (Cheminformatics)

Todd FarrellAdvisor (Strategy)

Frank ChangBoard Director

Funding, Partners & Investors

Founded in September 2019, we are a team of experienced AI/machine learning and business specialists applying state of the art generative AI to drug discovery in close collaboration with biopharmaceutical partners to bring new therapeutics to market across disease areas and positively impact lives.

Press

Press Release

Variational AI Adds Jennifer Hamilton as Advisor

Variational AI, developer of generative AI-based drug discovery platform for novel kinase inhibitors, today announced that it has added industry and scientific leader Jennifer Hamilton, Ph.D. as a company advisor.
Press Release

Generative Machine Learning Can Construct Smooth Chemical Search Spaces for Efficient Drug Discovery

The fundamental steps of rational drug design include the identification of a clinically relevant target protein, the discovery of “hit” ligands that weakly modulate the target protein in the de­sired manner.
Press Release

Handol Kim of Variational AI On The Future Of Artificial Intelligence

Recognition of the strategic importance of AI. The importance of AI is being elevated to a national level where capability is seen as a nationally-strategic priority.

Variational AI is hiring!

Please see open job listing below or contact us if you would like to join the team in the area of machine learning, computational medicinal chemistry, and business development.

View Positions

Contact Us